StockNews.com Begins Coverage on Otonomy (NASDAQ:OTIC)
StockNews.com Begins Coverage on Otonomy (NASDAQ:OTIC)
Analysts at StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research note issued to investors on Tuesday. The firm set a "hold" rating on the biopharmaceutical company's stock.
StockNews.com的分析师开始报道以下股票 Otonomy（纳斯达克股票代码：OTIC — 获取评级） 在周二发布给投资者的研究报告中。该公司对这家生物制药公司的股票设定了 “持有” 评级。
Separately, Piper Sandler downgraded Otonomy from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $3.00 to $0.50 in a research report on Thursday, October 13th.
另外，派珀·桑德勒在10月13日星期四的一份研究报告中将Otonomy的评级从 “增持” 下调至 “中性”，并将该股的目标价格从3.00美元下调至0.50美元。
Otonomy Stock Performance
Otonomy 股票表现
OTIC stock opened at $0.10 on Tuesday. The firm has a 50 day moving average of $0.11 and a 200-day moving average of $0.48. Otonomy has a 12-month low of $0.06 and a 12-month high of $2.59. The company has a market cap of $6.58 million, a price-to-earnings ratio of -0.13 and a beta of 1.47.
周二，OTIC股票开盘价为0.10美元。该公司的50天移动平均线为0.11美元，200天移动平均线为0.48美元。Otonomy创下12个月低点0.06美元，12个月高点2.59美元。该公司的市值为658万美元，市盈率为-0.13，beta值为1.47。
Institutional Trading of Otonomy
自主学的机构交易
Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP grew its stake in Otonomy by 129.2% in the 3rd quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 80,153 shares during the period. Requisite Capital Management LLC purchased a new stake in Otonomy in the 3rd quarter worth approximately $44,000. State Street Corp grew its stake in Otonomy by 5.1% in the 1st quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock worth $437,000 after acquiring an additional 8,839 shares during the period. Lynx1 Capital Management LP grew its stake in shares of Otonomy by 7,609.6% during the 3rd quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock valued at $682,000 after buying an additional 2,282,880 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Otonomy during the 3rd quarter valued at $1,621,000. 41.23% of the stock is owned by hedge funds and other institutional investors.
对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Two Sigma Investments LP在第三季度将其在Otonomy的股份增加了129.2％。Two Sigma Investments LP在此期间又收购了80,153股股票后，现在拥有这家生物制药公司142,183股股票，价值42,000美元。Requiend Capital Management LLC在第三季度购买了Otonomy的新股份，价值约为44,000美元。State Street Corp在第一季度将其在Otonomy的股份增长了5.1％。State Street Corp在此期间又收购了8,839股股票后，现在拥有这家生物制药公司的182,239股股票，价值43.7万美元。Lynx1 Capital Management LP在第三季度将其在Otonomy的股份增加了7,609.6％。Lynx1 Capital Management LP在此期间又购买了2,282,880股股票后，现在拥有这家生物制药公司的2312,880股股票，价值68.2万美元。最后，Point72 Asset Management L.P. 在第三季度购买了Otonomy的新股份，价值16.1万美元。该股中有41.23％由对冲基金和其他机构投资者持有。
Otonomy Company Profile
Otonomy 公司简介
(Get Rating)
（获取评分）
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Otonomy, Inc是一家生物制药公司，在美国开发神经病学疗法。该公司提供 OTO-313，一种持续暴露的N-甲基-D-天冬氨酸受体拮抗剂加环素配方，目前正在进行治疗耳鸣的II期临床试验；以及 OTO-413，一种大脑源性神经营养因子的持续暴露配方，正在进行用于修复耳蜗突触病和治疗噪音中言语听力障碍的IIa期临床试验。
See Also
另见
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Don't Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Macau a Sinking Ship for Wynn Resorts?
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- 免费获取 StockNews.com 关于自主学的研究报告（OTIC）的副本
- 千万不要错过上周爆发的这两家中型股科技公司
- 澳门是永利渡假村的沉船吗？
- Pinterest 是 2023 年值得关注的社交商务平台
- Walgreens Boots Alliance 的收益亏损对投资者有
- 为什么华纳兄弟发现是标准普尔最热门的股票
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Otonomy及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。